{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00","value":"0.00"}]}],"title":"Disease Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.98","value":"6.11"}]}],"title":"Side Effects of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.07","value":"11.11"}]}],"title":"Future Perspectives"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.33","value":"16.67"}]}],"title":"Body Image"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"QLQ-MY20 includes 20 questions across four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the disease symptoms scale = higher level of symptomatology.","dispersionType":"Standard Deviation","groups":[{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells expansion","id":"OG000","title":"Phase 2 600 x 10^6 Cells"}],"paramType":"MEAN","populationDescription":"All participants who received at least one infusion of JCARH125 with baseline and post-baseline assessment at the respective visit in phase 2 only as prespecified in the protocol","reportingStatus":"POSTED","timeFrame":"Baseline and visit 24 month","title":"Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (QLQ-MY20) in Phase 2","type":"SECONDARY","unitOfMeasure":"Score on a Scale"}